Indications -- Hepatitis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Hepatitis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	11/11/2005 12:32:31 PM
	of 312

Vertex Pharma Files for Mid-Stage Study Friday November 11, 11:21 am ET Vertex Pharma Files Paperwork With FDA to Begin Mid-Stage Clinical Trial for Hepatitis C Drug SAN FRANCISCO (AP) -- Drug maker Vertex Pharmaceuticals Inc. said Friday that it filed an investigational new drug application with the Food and Drug Administration to carry out a mid-stage clinical trial for its experimental hepatitis C drug. The company said it submitted the application with data showing that its VX-950 treatment reduced virus levels in patients by 25,000-fold in 14 days. Analysis of study data suggests that the treatment could reduce the virus to undetectable levels within 12 weeks, it said. Vertex shares rose 5 cents to $25.65 in morning trading on the Nasdaq. biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next